Serologicals Corporation Announces Expanded Multi-Year Distribution Agreement with Novo Nordisk; Celliance is Exclusive Distrib
2006年3月16日 - 11:00PM
ビジネスワイヤ(英語)
Celliance Corporation, a wholly owned subsidiary of Serologicals
Corporation (NASDAQ:SERO), announced today the execution of an
expanded four-year supply agreement with Novo Nordisk A/S that
provides Celliance the worldwide exclusive right to distribute Novo
Nordisk's recombinant human insulin in the cell culture market.
David A. Dodd, President and Chief Executive Officer of
Serologicals Corporation, commented on the supply agreement,
stating, "We are very pleased to have concluded this milestone
agreement with Novo Nordisk. It represents years of hard work and
successful collaboration on the part of both companies. Our
relationship with Novo Nordisk began more than a decade ago when
one of our predecessor companies began distributing Novo Nordisk's
insulin into the cell culture market. Our colleagues at Novo
Nordisk were quick to realize the importance of this market. They
permitted us to develop it by affording us a dependable supply of
the highest quality recombinant human insulin for our customers.
The agreement that we just concluded allows us to renew our
commitment to our cell culture customers for another four years. We
will continue to market this important product to our customers
under our Incelligent(TM) brand." Jesper Hoiland, Novo Nordisk's
Senior Vice President of International Operations, said, "Novo
Nordisk and Celliance have worked closely to build a leading
position in the insulin segment of the global market for cell
culture media. The new agreement creates a strong platform for
increased growth and keeps leadership also in this segment."
Celliance Corporation offers an expanding array of bioprocessing
products and services including diagnostic products and cell
culture media supplements. Key products include EX-CYTE(R), the
largest selling cell growth supplement, Probumin(TM), a proprietary
line of bovine serum albumin and Incelligent(TM), recombinant human
insulin. It is also the world's leading provider of monoclonal
antibodies for the blood typing industry. Celliance(TM) is a
Serologicals company based in Atlanta, GA. Serologicals Corporation
(NASDAQ: SERO), headquartered in Atlanta, GA., is a global leader
in developing and commercializing consumable biological products,
enabling technologies and services. Our customers include
researchers at major life science companies and leading research
institutions involved in key disciplines, such as neurology,
oncology, hematology, immunology, cardiology, proteomics,
infectious diseases, cell signaling and stem cell research. In
addition, we are the world's leading provider of monoclonal
antibodies for the blood typing industry. We employ a total of
approximately 1,000 people worldwide in three companies: Chemicon
International Inc., Upstate Group, LLC and Celliance Corporation.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. The company has the broadest diabetes product portfolio in
the industry, including the most advanced products within the area
of insulin delivery systems. In addition, Novo Nordisk has a
leading position within areas such as haemostasis management,
growth hormone therapy and hormone replacement therapy. Novo
Nordisk manufactures and markets pharmaceutical products and
services that make a significant difference to patients, the
medical profession and society. With headquarters in Denmark, Novo
Nordisk employs more than 22,000 employees in 79 countries, and
markets its products in 179 countries. Novo Nordisk's B shares are
listed on the stock exchanges in Copenhagen and London. Its ADRs
are listed on the New York Stock Exchange under the symbol `NVO'.
For more information regarding Serologicals Corporation, please
visit www.serologicals.com. For more information regarding
Celliance Corporation, please visit www.celliancecorp.com. For more
information regarding Novo Nordisk A/S, please visit
www.novonordisk.com. Serologicals(R) and EX-CYTE(R) are registered
trademarks of Serologicals Royalty Company. Incelligent(TM) and
Probumin(TM) are trademarks of Serologicals Royalty Company.
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 5 2024 まで 6 2024
Serologicals (NASDAQ:SERO)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Serologicals (MM) (ナスダック市場): 0 recent articles
その他のSerologicals Corporationニュース記事